One-Tube RNA Ligation and Amplification Method for Rapid Detection of Drug Resistant HIV
|
By LabMedica International staff writers Posted on 28 Oct 2015 |

Image: A schematic diagram of a new method that rapidly analyzes the RNA (green strands) of HIV for mutations (red dot) that convey drug resistance. The system does not require transcription of RNA to DNA, as current technologies do, and works within one solution (purple droplet) (Photo courtesy of Dr. Lei Zhang, Brown University).
By not requiring transcription of RNA to DNA, a novel one-tube method allows the rapid detection of drug resistant strains of HIV (human immunodeficiency virus).
In order to detect point mutations in RNA retroviruses, conventional ligase-mediated approaches require the reverse transcription of viral RNA genomes into DNA before separate ligation and amplification steps can be carried out.
To simplify this process, investigators at Brown University (Providence, RI, USA) developed one-step ligation on RNA amplification (LRA) method for the direct detection of RNA point mutations. The system operates directly on viral RNA rather than requiring extra, potentially error-prone steps to examine DNA derived from RNA. In a single tube, the system first combines two engineered probes (ligation). If a mutation is present, it then makes many copies of those combined probes (amplification) for detection.
The investigators used this technique for the detection of a common, clinically relevant HIV-1 reverse transcriptase drug-resistant point mutation, K103N, and compared it with allele-specific PCR and pyrosequencing methodology.
They reported in the November 2015 issue of the Journal of Molecular Diagnostics that the LRA test was sensitive enough to detect the K103N mutation in concentrations as low as one mutant per 10,000 strands of normal viral RNA. The LRA test required about two hours while the alternative technologies took as long as eight hours.
"LRA (ligation on RNA amplification) uniquely optimizes two enzymatic reactions—RNA-based ligation, and quantitative PCR (polymerase chain reaction) amplification—into a single system," said senior author Dr. Anubhav Tripathi, professor of engineering at Brown University. "Each HIV contains about 10,000 nucleotides, or building blocks, in its genetic material, and a drop of blood from a patient with resistant HIV can contain thousands to millions of copies of HIV. To find that one virus, out of thousands to millions, which is mutated at just a single nucleotide is like finding a needle in a haystack."
So far the LRA test has been shown to work on RNA that was derived from laboratory HIV strains, but it has not yet been applied to samples from circulating viruses from AIDS patients.
Related Links:
Brown University
In order to detect point mutations in RNA retroviruses, conventional ligase-mediated approaches require the reverse transcription of viral RNA genomes into DNA before separate ligation and amplification steps can be carried out.
To simplify this process, investigators at Brown University (Providence, RI, USA) developed one-step ligation on RNA amplification (LRA) method for the direct detection of RNA point mutations. The system operates directly on viral RNA rather than requiring extra, potentially error-prone steps to examine DNA derived from RNA. In a single tube, the system first combines two engineered probes (ligation). If a mutation is present, it then makes many copies of those combined probes (amplification) for detection.
The investigators used this technique for the detection of a common, clinically relevant HIV-1 reverse transcriptase drug-resistant point mutation, K103N, and compared it with allele-specific PCR and pyrosequencing methodology.
They reported in the November 2015 issue of the Journal of Molecular Diagnostics that the LRA test was sensitive enough to detect the K103N mutation in concentrations as low as one mutant per 10,000 strands of normal viral RNA. The LRA test required about two hours while the alternative technologies took as long as eight hours.
"LRA (ligation on RNA amplification) uniquely optimizes two enzymatic reactions—RNA-based ligation, and quantitative PCR (polymerase chain reaction) amplification—into a single system," said senior author Dr. Anubhav Tripathi, professor of engineering at Brown University. "Each HIV contains about 10,000 nucleotides, or building blocks, in its genetic material, and a drop of blood from a patient with resistant HIV can contain thousands to millions of copies of HIV. To find that one virus, out of thousands to millions, which is mutated at just a single nucleotide is like finding a needle in a haystack."
So far the LRA test has been shown to work on RNA that was derived from laboratory HIV strains, but it has not yet been applied to samples from circulating viruses from AIDS patients.
Related Links:
Brown University
Latest BioResearch News
- Single-Cell Method Measures RNA and Proteins to Reveal Immune Responses
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
- International Consensus Standardizes Tumor Microbiota Detection and Reporting
- Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
- Newly Identfied Genetic Variants in MND Support Prognosis and Family Testing
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
- Genetic Cause Identified for Severe Infant Epilepsy
- Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
- Researchers Identify Survival Pathway Undermining Targeted Cancer Drugs
- Large-Scale Study Maps DNA Damage Signatures Across Multiple Cancers
- Study Identifies Distinct Immune Signatures to Early Depression and Psychosis
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
- Genetic Discovery Could Improve Diagnosis of Drug-Resistant Epilepsy
- Genetic Discovery May Improve Diagnosis of Rare Dementia Subtype
- Mass Spectrometry Technique Detects Protein and Sugar Changes in Neurodegeneration
Channels
Clinical Chemistry
view channelNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read moreMolecular Diagnostics
view channel
Noninvasive Urine Test Predicts Recurrence After BCG in Bladder Cancer
Bladder cancer is among the most common malignancies in the United States and frequently recurs even when diagnosed at the non‑muscle invasive stage (NMIBC). After transurethral resection, many patients... Read more
Mesothelioma in Younger Adults Linked to Genetic Risk Factors
Mesothelioma is a rare malignancy of the pleura, historically linked to occupational asbestos exposure and most often diagnosed in older men. About 3,300 people are diagnosed each year in the United States,... Read moreHematology
view channel
Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read more
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read more
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read morePathology
view channel
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. The collaboration is designed to let clinicians at interested... Read moreGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more







